The purpose of this study is to investigate the effect of the study drug known as LY2157299 on red blood cells in participants with myelodysplastic syndromes (MDS). Participants with different degrees of disease (very low, low, and intermediate risk) will be studied. The study treatment is expected to last about 6 months for each participant.